利拉鲁肽与西马鲁肽减肥疗效比较:来自中东海湾地区的经验及文献综述。

IF 0.8 Q4 PHARMACOLOGY & PHARMACY
Wasim S El Nekidy, Haneen Hasan, Emna Abidi, Layth Al Sayegh, Ruba Z Dajani, Samer El-Kaissi, Safa B Hegazin, Jihad Mallat
{"title":"利拉鲁肽与西马鲁肽减肥疗效比较:来自中东海湾地区的经验及文献综述。","authors":"Wasim S El Nekidy, Haneen Hasan, Emna Abidi, Layth Al Sayegh, Ruba Z Dajani, Samer El-Kaissi, Safa B Hegazin, Jihad Mallat","doi":"10.1177/00185787251340645","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Available data comparing the efficacy of liraglutide and semaglutide in managing weight loss is limited. The objective of this study was to compare efficacy of both drugs on weight loss. <b>Methods:</b> A retrospective observational cohort study conducted at our quaternary care hospital from June 2018 to July 2022. The study included adults who received either liraglutide or semaglutide during the study period. The primary outcome was weight loss, while secondary outcomes included effects on HbA1c levels and lipid profile. <b>Results:</b> A total of 366 patients were analyzed (122 on liraglutide, 244 on semaglutide). The groups were comparable in mean age (51.00 ± 11.55 vs 51.16 ± 12.35 years, <i>P</i> = 0.521) and baseline mean weight (94.7 ± 19.5 vs 94.6 ± 19.9 kg, <i>P</i> = 0.989). After a median follow-up of 10 (6-17) months for the liraglutide group and 7.5 (6-11) months for the semaglutide group (<i>P</i> < 0.001), the resultant weights were 90.8 ± 19.6 kg for the liraglutide group and 91.1 ± 19.8 kg for the semaglutide group (<i>P</i> < 0.001) when comparing each group to its baseline separately. When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of -4 (-7 to 0) kg versus -3 (-6 to 0) kg for semaglutide (<i>P</i> = 0.867). The reduction in HbA1c levels with liraglutide was significantly less than with semaglutide: -0.2 (-0.5 to 0.3) versus -0.5 (-1.1 to 0.1), respectively, (<i>P</i> = 0.003). Both drugs significantly lowered LDL and triglycerides. Multivariable linear regression analysis confirmed no significant difference between the drugs [<i>B</i> -0.577, 95% CI -1.87 to 0.7; <i>P</i> = 0.38], while baseline weight, diabetes, and SGLT2 inhibitors were significant factors affecting weight. <b>Conclusion:</b> Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs. However, semaglutide was more effective in reducing HbA1c levels.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787251340645"},"PeriodicalIF":0.8000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095202/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.\",\"authors\":\"Wasim S El Nekidy, Haneen Hasan, Emna Abidi, Layth Al Sayegh, Ruba Z Dajani, Samer El-Kaissi, Safa B Hegazin, Jihad Mallat\",\"doi\":\"10.1177/00185787251340645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> Available data comparing the efficacy of liraglutide and semaglutide in managing weight loss is limited. The objective of this study was to compare efficacy of both drugs on weight loss. <b>Methods:</b> A retrospective observational cohort study conducted at our quaternary care hospital from June 2018 to July 2022. The study included adults who received either liraglutide or semaglutide during the study period. The primary outcome was weight loss, while secondary outcomes included effects on HbA1c levels and lipid profile. <b>Results:</b> A total of 366 patients were analyzed (122 on liraglutide, 244 on semaglutide). The groups were comparable in mean age (51.00 ± 11.55 vs 51.16 ± 12.35 years, <i>P</i> = 0.521) and baseline mean weight (94.7 ± 19.5 vs 94.6 ± 19.9 kg, <i>P</i> = 0.989). After a median follow-up of 10 (6-17) months for the liraglutide group and 7.5 (6-11) months for the semaglutide group (<i>P</i> < 0.001), the resultant weights were 90.8 ± 19.6 kg for the liraglutide group and 91.1 ± 19.8 kg for the semaglutide group (<i>P</i> < 0.001) when comparing each group to its baseline separately. When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of -4 (-7 to 0) kg versus -3 (-6 to 0) kg for semaglutide (<i>P</i> = 0.867). The reduction in HbA1c levels with liraglutide was significantly less than with semaglutide: -0.2 (-0.5 to 0.3) versus -0.5 (-1.1 to 0.1), respectively, (<i>P</i> = 0.003). Both drugs significantly lowered LDL and triglycerides. Multivariable linear regression analysis confirmed no significant difference between the drugs [<i>B</i> -0.577, 95% CI -1.87 to 0.7; <i>P</i> = 0.38], while baseline weight, diabetes, and SGLT2 inhibitors were significant factors affecting weight. <b>Conclusion:</b> Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs. However, semaglutide was more effective in reducing HbA1c levels.</p>\",\"PeriodicalId\":13002,\"journal\":{\"name\":\"Hospital Pharmacy\",\"volume\":\" \",\"pages\":\"00185787251340645\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095202/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/00185787251340645\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787251340645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:比较利拉鲁肽和西马鲁肽在减肥方面的疗效的现有数据有限。这项研究的目的是比较两种药物在减肥方面的疗效。方法:2018年6月至2022年7月在我院第四护理医院进行回顾性观察队列研究。该研究包括在研究期间接受利拉鲁肽或西马鲁肽治疗的成年人。主要结局是体重减轻,次要结局包括对HbA1c水平和血脂的影响。结果:共分析366例患者(利拉鲁肽122例,西马鲁肽244例)。两组的平均年龄(51.00±11.55岁vs 51.16±12.35岁,P = 0.521)和基线平均体重(94.7±19.5 kg vs 94.6±19.9 kg, P = 0.989)具有可比性。利拉鲁肽组中位随访时间为10(6-17)个月,西马鲁肽组中位随访时间为7.5(6-11)个月(P P P = 0.867)。利拉鲁肽组HbA1c水平的降低明显小于西马鲁肽组:分别为-0.2(-0.5至0.3)和-0.5(-1.1至0.1),(P = 0.003)。两种药物都能显著降低低密度脂蛋白和甘油三酯。多变量线性回归分析证实两种药物间无显著差异[B -0.577, 95% CI -1.87 ~ 0.7;P = 0.38],而基线体重、糖尿病和SGLT2抑制剂是影响体重的显著因素。结论:利拉鲁肽与西马鲁肽均有较好的减肥效果,两药间无显著性差异。然而,西马鲁肽在降低HbA1c水平方面更有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.

Objective: Available data comparing the efficacy of liraglutide and semaglutide in managing weight loss is limited. The objective of this study was to compare efficacy of both drugs on weight loss. Methods: A retrospective observational cohort study conducted at our quaternary care hospital from June 2018 to July 2022. The study included adults who received either liraglutide or semaglutide during the study period. The primary outcome was weight loss, while secondary outcomes included effects on HbA1c levels and lipid profile. Results: A total of 366 patients were analyzed (122 on liraglutide, 244 on semaglutide). The groups were comparable in mean age (51.00 ± 11.55 vs 51.16 ± 12.35 years, P = 0.521) and baseline mean weight (94.7 ± 19.5 vs 94.6 ± 19.9 kg, P = 0.989). After a median follow-up of 10 (6-17) months for the liraglutide group and 7.5 (6-11) months for the semaglutide group (P < 0.001), the resultant weights were 90.8 ± 19.6 kg for the liraglutide group and 91.1 ± 19.8 kg for the semaglutide group (P < 0.001) when comparing each group to its baseline separately. When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of -4 (-7 to 0) kg versus -3 (-6 to 0) kg for semaglutide (P = 0.867). The reduction in HbA1c levels with liraglutide was significantly less than with semaglutide: -0.2 (-0.5 to 0.3) versus -0.5 (-1.1 to 0.1), respectively, (P = 0.003). Both drugs significantly lowered LDL and triglycerides. Multivariable linear regression analysis confirmed no significant difference between the drugs [B -0.577, 95% CI -1.87 to 0.7; P = 0.38], while baseline weight, diabetes, and SGLT2 inhibitors were significant factors affecting weight. Conclusion: Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs. However, semaglutide was more effective in reducing HbA1c levels.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信